Home » Topics » BioWorld Science

BioWorld Science
RSS

Cracking influenza's egg code

June 4, 2019

Fibroblasts specialize, too

June 4, 2019

Phase II COPD study finds no effect of CHF-6001 on lung function

June 3, 2019

Gamida Cell presents clinical and translational data from phase I/II study of omidubicel

June 3, 2019

Preliminary activity seen with U3-1402 in resistant EGFR-mutant non-small cell lung cancer

June 3, 2019

Talaris presents quality-of-life data on FCR-001

June 3, 2019

Avacta plans clinical trial of TMAC linker next year

June 3, 2019

Phase I results provided for JNJ-61186372 in non-small cell lung cancer

June 3, 2019

Kite, Humanigen evaluate investigational combination therapy for lymphoma

June 3, 2019

FDA responds to Oncology Venture's IND for proposed pivotal phase III study of LiPlaCis

June 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.